ABSTRACT
Background: Cypermethrin is a well know agricultural pesticide used in the developing countries. It is associated with significant toxic potential on human health. Hence the present study was aimed to evaluate the protective role of Amomum subulatum against cypermethrin induced haematalogical changes in Wistar albino rats.Methods: The albino rats were divided into five different groups of six rats each. Group I considered as normal control, group II cypermethrin control (25mg/kg body weight p.o.), group III only test drug and group IV and V administered with cypermethrin 25mg/kg body weight along test drug 1.08 and 2.16mg/kg body weight for 28 consecutive days. At the end of 28th day blood was withdrawn and total haematalogical parameters were estimated.Results: In the cypermethrin control there was significant reduction in the WBC, Platelet, MCHC and considerable reduction in the haemoglobulin concentration in comparison to normal control. The test drug administered at both dose levels was significantly reversed the cypermethrin induced changes in haematalogical parameters.Conclusions: Authors can conclude that the Amomum subulatum has potency to reverse the cypermethrin induced haematalogical changes.
ABSTRACT
Obesity is a chronic pathological condition characterized by an increased body fat accumulation to the extent that it may have an adverse effect on the health. Depression is the most common co-morbidity of obesity, which may cause the Binge Eating Disorder (BED), leading to morbid obesity. In the present project a dispersible 60mg Orlistat (ORST) and β-cyclodextrin (β-CD), (1:2M) complexed core tablet is press coated with the taste masked 75mg Venlafaxine Hcl. (VLFXN) microparticles, prepared with Eudragit EPO (1:3), by emulsification solvent evaporation method, to obtain the chewable tablet-in-tablet dosage form. A Reverse phase (RP)-HPLC method was developed for the simultaneous estimation of ORST and VLFXN in the formulation. The optimized formulation was palatable and there was no drug excipients interaction which was confirmed by IR Spectrum. Press coated, tablet-in-tablets were evaluated for physicochemical properties. All the values obtained were within the standard limits. And in the in-vitro dissolution study the release of both drugs, ORST and VLFXN at the end of 15mins was found to be 86% and 92% respectively. Hence, the developed chewable tablet-in-tablet formulation of ORST and VLFXN can be a viable drug delivery system for treating patients with obesity and BED.